Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant.
Location: China
Employees: 51-200
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | SymBiosis | symbiosis.... |
Mentions in press and media 5
| Date | Title | Description |
| 02.04.2026 | CHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala | SHANGHAI, April 2, 2026 /PRNewswire/ -- The 12th Annual China Healthcare Investment Conference (CHIC 2026) capped the first day of its two-day program with a celebratory Awards Gala Dinner held at The Ritz-Carlton Hotel Pudong, Shanghai. Th... |
| 18.09.2025 | Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting | YANTAI, China, Sept. 18, 2025 /PRNewswire/ -- RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-target fusio... |
| 03.02.2025 | This Startup Is Billionaire Reid Hoffman's Next Big Bet Hoffman sold LinkedIn, which he co-founded, to Microsoft for $26.2 billion in 2016. | LinkedIn co-founder Reid Hoffman became a billionaire when Microsoft bought LinkedIn in 2016 for $26.2 billion in cash, and he has also made his fortune on high-return investments in more than 80 tech startups, including Airbnb, Groupon, an... |
| 05.03.2024 | Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | - |
| 29.09.2022 | Vor Bio opts to keep manufacturing operations in-house for developing stem cell, CAR-T therapies | While it is not uncommon for a biotech to go down the route of having the product manufactured by a contract organization, one small biotech is looking to keep its card close to its chest. Vor Biopharma has started manufac... |